GLP-1 Agonists Linked to Cardiovascular Outcomes in MASLD Patients | Retatrutide News

GLP-1 receptor agonists are linked to improved cardiovascular outcomes in MASLD patients. This study may impact future research on drugs like Retatrutide.
Clinical Trials · November 1, 2026